Hepatic Cancer

Phase I data evaluating BAY 43-9006 plus conventional chemo released

Published in Cancer Weekly, December 7th, 2004

Bayer Pharmaceuticals Corporation (BAY) and Onyx Pharmaceuticals, Inc., (ONXX) announced results from several phase I clinical trials of BAY 43-9006 administered in combination with conventional chemotherapy drugs in patients with various tumor types, including hepatic cancer and colorectal cancer.

The data were presented at the 29th European Society of Medical Oncology (ESMO) meeting in Vienna, Austria.

Data from these phase I safety and pharmacokinetic (metabolism) interaction studies showed that BAY 43-9006 could be combined with the other anticancer agents evaluated (doxorubicin, oxaliplatin, fluorouracil and leucovorin).

In...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-12-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry